{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:08:10Z","timestamp":1789398490609,"version":"build-2803163510"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes for Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004411","name":"Heart & Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"name":"British Heart Foundation and drug"},{"DOI":"10.13039\/100008459","name":"University of Calgary","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Patients with minor ischaemic stroke (NIHSS \u2264\u20095) and intracranial occlusion or focal perfusion abnormality \u2264\u200912\u00a0h of onset did not benefit from intravenous tenecteplase compared to non-thrombolytic standard care (control) in the Tenecteplase vs Standard of Care for Minor Ischaemic Stroke with Proven Occlusion (TEMPO-2) trial. We tested whether tenecteplase was associated with better outcomes in subgroups defined by baseline vessel occlusion status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>In this secondary analysis of the randomised, controlled, blinded TEMPO-2 trial, patients were divided into 3 subgroups: complete occlusion (revised arterial occlusive lesion score 0), near occlusion (score 1) and no visible occlusion (focal perfusion abnormality present). The primary outcome was return to pre-stroke neurological functioning or better, assessed with 90-day mRS. Outcomes were analysed using a generalised linear model adjusted for age, sex, onset-to-randomisation time and baseline stroke severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 881 patients, complete occlusion was present in 218 in the control and 216 in the tenecteplase arm, near occlusion in 102 and 92 and no visible occlusion in 130 and 123, respectively. At baseline, there were longer treatment delays in the control arm with near occlusion, and older age, more hypertension and higher creatinine levels in the tenecteplase arm with complete occlusion. We found no difference in the primary outcome between tenecteplase and control in any subgroup (no visible occlusion: adjusted RR 1.03 [95% CI, 0.90\u20131.18]; near occlusion: adjusted RR 0.85 [95% CI, 0.71\u20131.01]; complete occlusion: adjusted RR 1.00 [95% CI, 0.89\u20131.12]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and conclusion<\/jats:title>\n                    <jats:p>There was no difference in outcome between tenecteplase and standard care for patients with mild stroke based on their baseline vessel occlusion status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov: NCT02398656.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/esj\/aakag111","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:30:42Z","timestamp":1789396242000},"source":"Crossref","is-referenced-by-count":0,"title":["Tenecteplase versus standard care for minor ischaemic stroke according to the baseline occlusion status in TEMPO-2 trial"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-0597","authenticated-orcid":false,"given":"Silja","family":"R\u00e4ty","sequence":"first","affiliation":[{"name":"Department of Neurology, Helsinki University Hospital and University of Helsinki , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9095-2344","authenticated-orcid":false,"given":"Daniel","family":"Strbian","sequence":"additional","affiliation":[{"name":"Department of Neurology, Helsinki University Hospital and University of Helsinki , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3647-0904","authenticated-orcid":false,"given":"Nishita","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Neurology, Rady Faculty of Health Sciences, University of Manitoba , Winnipeg, Manitoba ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2398-5039","authenticated-orcid":false,"given":"Shabnam","family":"Vatanpour","sequence":"additional","affiliation":[{"name":"Departments of Clinical Neurosciences, Radiology and Community Health Sciences, Cumming School of Medicine, Hotchkiss Brain Institute, University of Calgary , Calgary ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-5846","authenticated-orcid":false,"given":"Liisa","family":"Tomppo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Helsinki University Hospital and University of Helsinki , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5520-2070","authenticated-orcid":false,"given":"Aravind","family":"Ganesh","sequence":"additional","affiliation":[{"name":"Departments of Clinical Neurosciences, Radiology and Community Health Sciences, Cumming School of Medicine, Hotchkiss Brain Institute, University of Calgary , Calgary ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3632-9433","authenticated-orcid":false,"given":"Bruce C V","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne , Parkville, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8874-2487","authenticated-orcid":false,"given":"Mark W","family":"Parsons","sequence":"additional","affiliation":[{"name":"Department of Neurology, Liverpool Hospital , Liverpool ,","place":["Australia"]},{"name":"School of Clinical Medicine, South Western Sydney Campus, University of New South Wales , Liverpool ,","place":["Australia"]},{"name":"Sydney Brain Centre, Ingham Institute of Applied Medical Research , Liverpool ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Hill","sequence":"additional","affiliation":[{"name":"Departments of Clinical Neurosciences, Radiology and Community Health Sciences, Cumming School of Medicine, Hotchkiss Brain Institute, University of Calgary , Calgary ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5090-5105","authenticated-orcid":false,"given":"Shelagh B","family":"Coutts","sequence":"additional","affiliation":[{"name":"Departments of Clinical Neurosciences, Radiology and Community Health Sciences, Cumming School of Medicine, Hotchkiss Brain Institute, University of Calgary , Calgary ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"2026091410301244600_ref1","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1177\/2396987321989865","article-title":"European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke","volume":"6","author":"Berge","year":"2021","journal-title":"Eur Stroke J"},{"key":"2026091410301244600_ref2","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/STR.000000000000015","article-title":"2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"key":"2026091410301244600_ref3","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","article-title":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials","volume":"384","author":"Emberson","year":"2014","journal-title":"Lancet"},{"key":"2026091410301244600_ref4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2018.8496","article-title":"Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: the PRISMS randomized clinical trial","volume":"320","author":"Khatri","year":"2018","journal-title":"JAMA"},{"key":"2026091410301244600_ref5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamaneurol.2024.4688","article-title":"Prourokinase vs standard care for patients with mild ischemic stroke: the PUMICE randomized clinical trial","volume":"82","author":"Xiong","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026091410301244600_ref6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12916-024-03820-2","article-title":"Effect of intravenous urokinase vs best medicine treatment on functional outcome for patients with acute minor stroke (TRUST): a randomized controlled trial","volume":"23","author":"Tao","year":"2025","journal-title":"BMC Med"},{"key":"2026091410301244600_ref7","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/S0140-6736(24)00921-8","article-title":"Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial","volume":"403","author":"Coutts","year":"2024","journal-title":"Lancet"},{"key":"2026091410301244600_ref8","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1001\/jama.2023.7827","article-title":"Dual antiplatelet therapy vs alteplase for patients with minor nondisabling acute ischemic stroke: the ARAMIS randomized clinical trial","volume":"329","author":"Chen","year":"2023","journal-title":"JAMA"},{"key":"2026091410301244600_ref9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"2026091410301244600_ref10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"2026091410301244600_ref11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"key":"2026091410301244600_ref12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1001\/jama.2018.12498","article-title":"Association of clinical, imaging, and thrombus characteristics with recanalization of visible intracranial occlusion in patients with acute ischemic stroke","volume":"320","author":"Menon","year":"2018","journal-title":"JAMA"},{"key":"2026091410301244600_ref13","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1161\/01.STR.0000258112.14918.24","article-title":"The impact of recanalization on ischemic stroke outcome: a meta-analysis","volume":"38","author":"Rha","year":"2007","journal-title":"Stroke"},{"key":"2026091410301244600_ref14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/17474930241253702","article-title":"A Randomized Controlled Trial of Tenecteplase Versus Standard of Care for Minor Ischemic Stroke with Proven Occlusion (TEMPO-2): rational and design of a multicenter, randomized open-label clinical trial","volume":"19","author":"Singh","year":"2024","journal-title":"Int J Stroke"},{"key":"2026091410301244600_ref15","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(00)02237-6","article-title":"Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score","volume":"355","author":"Barber","year":"2000","journal-title":"Lancet"},{"key":"2026091410301244600_ref16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1212\/WNL.0000000000000572","article-title":"Factors associated with unfavorable outcome in minor ischemic stroke","volume":"83","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"2026091410301244600_ref17","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1161\/01.str.28.10.1876","article-title":"Is the EuroQol a valid measure of health-related quality of life after stroke?","volume":"28","author":"Dorman","year":"1997","journal-title":"Stroke"},{"key":"2026091410301244600_ref18","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1161\/STROKEAHA.115.010049","article-title":"The Heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy","volume":"46","author":"Kummer","year":"2015","journal-title":"Stroke"},{"key":"2026091410301244600_ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.4152","article-title":"Thrombolysis with tenecteplase for minor disabling stroke: secondary analysis of the TEMPO-2 randomized clinical trial","volume":"82","author":"Zhang","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026091410301244600_ref20","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1161\/STROKEAHA.124.048248","article-title":"Dual antiplatelet versus alteplase for early neurologic deterioration in minor stroke with versus without large vessel occlusion: prespecified post hoc analysis of the ARAMIS trial","volume":"55","author":"Cui","year":"2024","journal-title":"Stroke"},{"key":"2026091410301244600_ref21","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1056\/NEJMoa2408954","article-title":"Endovascular treatment for stroke due to occlusion of medium or distal vessels","volume":"392","author":"Psychogios","year":"2025","journal-title":"N Engl J Med"},{"key":"2026091410301244600_ref22","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1056\/NEJMoa2411668","article-title":"Endovascular treatment of stroke due to medium-vessel occlusion","volume":"392","author":"Goyal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026091410301244600_ref23","doi-asserted-by":"publisher","first-page":"e214925","DOI":"10.1212\/WNL.0000000000214925","article-title":"Outcomes after minor ischemic stroke in older patients treated with IV thrombolysis vs standard of care in the TEMPO-2 trial","volume":"106","author":"Ganesh","year":"2026","journal-title":"Neurology"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/11\/9\/aakag111\/71074642\/aakag111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/11\/9\/aakag111\/71074642\/aakag111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:30:44Z","timestamp":1789396244000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/doi\/10.1093\/esj\/aakag111\/8793669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,5]]}},"URL":"https:\/\/doi.org\/10.1093\/esj\/aakag111","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9]]},"article-number":"aakag111"}}